Michael is the Chief Financial Officer at RA Capital Management. In his role at Catamaran, he helped secure a Series A financing with a syndicate of leading investors, rapidly recruit an experienced cell therapy team, access enabling technologies, build a broad patent estate, and design external communication strategies. Tess has a BA with a double major in Economics and Peace & Conflict studies from the University of Toronto, Canada. Daniels primary responsibility at RA Capital is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Toms primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Kats primary responsibility is supporting newcos, portfolio companies and executives within RAVen, focusing on strategic finance. Ross has a BS in Biochemistry from University of Oregon and a PhD in Pharmacology & Molecular Sciences from Johns Hopkins University. Most recently, Brendan served as Tax Director at PwC Asset & Wealth Management. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. He previously worked as a corporate attorney at Foley Hoag LLP and Cooley LLP. Ernestos primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. In addition to The Great American Drug Deal, he is the author of The Entrepreneurs Guide to a Biotech Startup. Americas +1 212 318 2000. Prior to Longitude Capital, Cristina held an Associate Analyst role in Biotechnology Equity Research at Cowen. He holds a BA from Cornell University and a PhD in Virology from Harvard University. She was also an Entrepreneurial Fellow at VentureLabs for Flagship Pioneering. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Ed began his career working with neurologically active compounds at Allergan, CoCensys, and Serono. Adam has led and advised companies in diverse areas such as digital health, materials and diagnostics, and has served as Director on the board of multiple venture-backed companies. Prior to Tamarack, Brian held roles as Associate Portfolio Manager and Research Analyst, Healthcare, at Sonar Capital Management. Cameron is a Senior Research Assistant at RA Capital Management. In this role, Gerald is responsible for evaluating new technology and novel biology to originate and support the generation of new companies in collaboration with RAVens Venture Partners and EIRs. Anas primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Candice has a BS in Mass Communications from Emerson College. Prior to Sage, he had a 14-year tenure at Biogen in various business and commercial roles. Early in his career, Mr. Grau worked with multi-national pharma companies including Pharmacia, Pharmacia & Upjohn, and Eisai as a management consultant focused on corporate strategy, M&A, and new product launch. While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry. Jesse earned his Ph.D. in Biological Chemistry from MIT and was a Harvard Origins Research Fellow. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. His doctoral research focused on breast cancer metastasis. Michael has a BS in Business Administration from Boston University with concentrations in Finance and Accounting. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. in Biomedical Anthropology from the University of Pennsylvania. Peter Kolchinsky @PeterKolchinsky 2h So competition among vaccine innovators required collaboration to expand production and rewards were high enough to hire all capable people in the world to work on this. Raj previously worked as a Senior Project Leader at Altus Pharmaceuticals, a spin-off company of Vertex Pharmaceuticals, where he assessed business processes and implemented system solutions across all areas of science. Gabe has a BS in Biology from Cornell University and a PhD in Biology from Northeastern University. Drew has a BS in Chemical Engineering from University of Virginia and a PhD in Chemical Engineering from Massachusetts Institute of Technology. Habib received his BBA in Marketing & Finance and his MBA in International Business from University of New Brunswick. Josh Resnick is a Senior Managing Director at RA Capital Management. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Jaimie previously held roles in non-profit and medical settings and worked at Goldman Sachs where she was an Executive Assistant. Sonia has a BA in Chemistry and a PhD in Bioengineering, both from the University of Pennsylvania. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. Emily Greenis a Visual Identity Designer at RA Capital Management. Barrie's 1911 novel. Jacqueline has a BS with a double major in Molecular and Cellular Biology & Earth and Planetary Sciences from Johns Hopkins University. Joe DeMaio is IT Operations Associate at RA Capital Management. Ernesto Gonzalez is a Business Systems Manager at RA Capital. Kevin Grosselin is RA Ventures Associate at RA Ventures (RAVen). More recently, Scott founded MissionGBM, a global community and resource focused on advancing brain cancer therapeutics development and care delivery. He also holds a B.A. She also gained administrative and client services experience in roles she held at Life Time Athletic, EF Education First, and at Beth Israel Deaconess Hospital ICU. TJ is a Senior Fund Accountant at RA Capital Management. Raj holds a BA from Cornell University, where he majored in Chemistry. While at Tamarack, he managed coverage expansion into commercial-stage biotech, pharma, and specialty pharma sectors. Prior to RA, Dan spent three years in Systems Engineer and Technical Consultant roles at Withum Smith + Brown, where he provided cloud and hybrid implementation guidance for clients within industries such as healthcare, construction, and fitness. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. I would love to talk to the 1 out of 7 VCs who thinks non-orphan small molecules for older patients are just as investable post The film delves into the psychological roots of Hook's anger, Peter Pan's everlasting childhood, and Wendy's reluctance to face adulthood. Prior to this role, Anurag was at Orbimed Advisors where he served as Vice President, Structured Growth Capital and Royalty Opportunities. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. Peter Kolchinsky Founder and CEO RA Capital Management. A trained cardiologist, he has held academic faculty positions at the University of California, San Francisco (UCSF) and the University of Texas Southwestern Medical Center. Habib has earned his Director Professionalism Certificate from the National Association of Corporate Directors. Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. Bretts primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Michael has more than two decades of experience in immuno-oncology and immunology research in both large pharma and biotech settings. James McArthur is an Advisor for RA Capital Management. Daniel has a BS in Mechanical Engineering from Lehigh University and a MS in Energy Policy & Climate from Johns Hopkins University. Also joining the Board as observers are Nimish Shah, MPH, MBA, Vice President at Venrock, and Peter Kolchinsky, Ph.D., Managing Director of RA Capital Management. MarketScreener: Created by Investors for Investors! He researched HIV at Harvard, where he earned his PhD, and then co-founded RA Capital Management, a Boston-based life-sciences investment firm focused on funding and creating companies developing new medicines. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Most importantly, this book describes concrete . Steve's survey is fascinating. Kathryn Spencer is an Executive Assistant at RA Capital Management. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Special Projects Operations Manager/Chief of Staff. Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. Kathryn previously held roles as Executive Assistant and Office Manager at Kojin Tx. Henry Stusnick is an Associate at RA Capital Management. Parents Need to Know. Nate Davis is an Analyst on the Investment Team at RA Capital Management. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Ryan Russell is a Fund Accountant at RA Capital Management. Natalie holds a BA in Psychology from William Paterson University and a MA in Psychology from Seton Hall University. He co-founded and runs the Boston-based investment firm RA Capital Management; writes and teaches about biomedical entrepreneurship and its potential to transform global health; serves on the boards of several public and private drug development companies; and lives in Massachusetts with his historian/equestrian wife, strong-willed children, and Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Most recently, David served as Director of Operations at Corbin Capital Partners, LP. He was a faculty member at the University of Rochester School of Medicine prior to joining Merck Research Laboratories in 2004. Alyssa Larson is an Associate Director within the TechAtlas division at RA Capital Management. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. April 28, 2023 9:39am. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Emily holds a BS in Graphic Design from James Madison University. Brendan has more than 18 years of experience as a tax professional. Tom has a BS in Physiological Sciences from University of California Los Angeles. Jennas primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Shan Shans primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Lucas primary responsibilities are to advise on regulatory matters and assist in the development, implementation, and testing of the compliance program. Gunes Bozkurt is an Analyst on the Venture Team at RA Capital Management. Prior to RA, Laura was a Principal at MP Healthcare Venture Management. Peter Kolchinsky An excellent example of when knowledge meets power, former Harvard virology doctoral recipient Kolchinsky has put his brainpower to work behind RA Capital Management, with astonishing results in biotech specialization. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. As Head of Vaccines, he is leading the RA vaccine team to support our evidence-based investment strategy. in Anthropology and Natural Sciences and an M.S. Peter Kolchinsky, Ph.D. Board Member Peter Kolchinsky, Ph.D., has more than 18 years of experience in healthcare investing and is the founder of and a managing partner at RA Capital. Adam was also an advisor and investor in A Late Quartet, an entrepreneurial feature film centered on a cellist diagnosed with Parkinsons disease, starring Philip Seymour Hoffman, Catherine Keener and Christopher Walken. Katherine Terranova is an Associate within the TechAtlas division of RA Capital Management. Prior to RAVen, Cosmas was an Entrepreneur in Residence at Third Rock Ventures and was part of the teams that built Asher Bio (cell targeted biologics for oncology/autoimmune diseases) and Septerna (GPCR focused drug discovery) as well as other NewCOs in development. Brian is a IT Operations Manager at RA Capital Management. Dings primary responsibility at RA Capital is to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Ed Monaghan is an EIR at RA Capital. He was previously a marketing manager at Brighton House Associates, assisting with fundraising campaigns for a diverse group of investment managers, including private equity, venture capital, real estate, and hedge funds.
H2geo Molecular Shape,
Providence Strategic Growth Fund V,
Articles P